Asher Chanan-Khan

Asher A. Chanan-Khan, M.D. is dedicated to advancing and discovering treatments for patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and multiple myeloma. For over two decade, Professor Chanan-Khan has been engaged in the development of novel therapeutics through laboratory and clinical research. His expertise is in preclinical target validation and drug evaluation directed towards early phase clinical trials. Dr. Chanan-Khan has sserved as the principal investigator or co-principal investigator on numerous clinical trials for patients with these disorders authoring over 200 publications. Administratively, Dr. Chanan-Khan completed his tenure as the Chair of Hematology & Oncology at Mayo Clinic in Florida, member of the Florida Cancer Control & Research Advisory Council (CCRAB) and past member of the NCCN CLL and Myeloma Guideline committees. He is an active member of ASH and ASCO. Dr. Chanan-Khan is an animal conservationist volunteering as a member of the Board on Jacksonville Zoo and a passionate supporter of the non-profit organisation "Open Hands Global" (https://www.openhandsglobal.org) committed to fighting bonded slavery in SouthEast Asia.

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a BS in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University.
Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his residency and hematology and medical oncology fellowship.
Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Asher A. Chanan-Khan, M.D. is dedicated to advancing and discovering treatments for patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and multiple myeloma. For over two decade, Professor Chanan-Khan has been engaged in the development of novel therapeutics through laboratory and clinical research. His expertise is in preclinical target validation and drug evaluation directed towards early phase clinical trials. Dr. Chanan-Khan has sserved as the principal investigator or co-principal investigator on numerous clinical trials for patients with these disorders authoring over 200 publications. Administratively, Dr. Chanan-Khan completed his tenure as the Chair of Hematology & Oncology at Mayo Clinic in Florida, member of the Florida Cancer Control & Research Advisory Council (CCRAB) and past member of the NCCN CLL and Myeloma Guideline committees. He is an active member of ASH and ASCO. Dr. Chanan-Khan is an animal conservationist volunteering as a member of the Board on Jacksonville Zoo and a passionate supporter of the non-profit organisation "Open Hands Global" (https://www.openhandsglobal.org) committed to fighting bonded slavery in SouthEast Asia.

Dr. Justin Taylor is the Pap Corp Endowed Professor in Leukemia and a physician-scientist in the Division of Hematology and Department of Medicine at the University of Miami Miller School of Medicine. He serves as the Translational Leader for the Leukemia Group and is a full member of the Sylvester Comprehensive Cancer Center. Before joining Sylvester in 2020, he completed his medical training at Brigham & Women’s Hospital, part of Harvard Medical School, and his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center. In addition to seeing patients, he performs laboratory research and has received several awards, including the Stanley J. Glaser Award and the Schally Research Award from the Department of Medicine and the Outstanding Basic/Translational Researcher of the Year from Sylvester Comprehensive Cancer Center. Dr. Taylor was recently elected to the American Society of Clinical Investigation. His research focuses on understanding and overcoming resistance to targeted therapies in hematologic cancers. His group published on BTK mutations causing resistance to covalent and non-covalent BTK inhibitors and classified them based on kinase activity into kinase proficient and kinase impaired. They went on to show that both types of mutations are susceptible to BTK degrader therapies in clinical trials. Recent work is focused on resistance mechanisms to BTK degraders.